SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-263158
Filing Date
2023-10-25
Accepted
2023-10-25 17:05:59
Documents
15
Period of Report
2023-10-23
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d533607d8k.htm   iXBRL 8-K 32677
2 EX-4.1 d533607dex41.htm EX-4.1 72365
3 EX-4.2 d533607dex42.htm EX-4.2 94455
4 EX-10.1 d533607dex101.htm EX-10.1 187097
  Complete submission text file 0001193125-23-263158.txt   617726

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA algs-20231023.xsd EX-101.SCH 2837
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE algs-20231023_lab.xml EX-101.LAB 18739
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE algs-20231023_pre.xml EX-101.PRE 11699
9 EXTRACTED XBRL INSTANCE DOCUMENT d533607d8k_htm.xml XML 3481
Mailing Address ONE CORPORATE DR., 2ND FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address ONE CORPORATE DR., 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 (800) 466-6059
Aligos Therapeutics, Inc. (Filer) CIK: 0001799448 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39617 | Film No.: 231346676
SIC: 2836 Biological Products, (No Diagnostic Substances)